Pharmacokinetic trial of Medidur begins:
This article was originally published in Clinica
Alimera Sciences and pSivida have kicked off the first human pharmacokinetic trial of Medidur, the companies' drug-eluting implant for the treatment of diabetic macular oedema. Medidur is injected intra-vitreally and delivers a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years. The new three-year study will also provide information on the location of Medidur FA in the eye after insertion and drug levels in the anterior chamber. Currently in a global phase III trial in around 900 patients, the device is the subject of a co-development agreement between Alimera, of Alpharetta, Georgia, and Perth, Australia-based pSivida.
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.